Evidence map›Paper›PMID 40138219›Full record

Trial reportClinical and translational science2025

Comparison of Molnupiravir Exposure-Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID-19.

Akshita Chawla, Ruthie Birger, Brian M Maas, Youfang Cao, Hong Wan, Julie Strizki, Arthur Fridman, Amanda Paschke, Carisa de Anda, Wei Gao and 6 more

Abstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Akshita ChawlaMerck & Co., Inc., Rahway, New Jersey, USA.
Ruthie BirgerMerck & Co., Inc., Rahway, New Jersey, USA.
Brian M MaasMerck & Co., Inc., Rahway, New Jersey, USA.ORCID 0000-0002-2410-4379
Youfang CaoMerck & Co., Inc., Rahway, New Jersey, USA.
Hong WanMerck & Co., Inc., Rahway, New Jersey, USA.
Julie StrizkiMerck & Co., Inc., Rahway, New Jersey, USA.
Arthur FridmanMerck & Co., Inc., Rahway, New Jersey, USA.
Amanda PaschkeMerck & Co., Inc., Rahway, New Jersey, USA.
Carisa de AndaMerck & Co., Inc., Rahway, New Jersey, USA.
Wei GaoMerck & Co., Inc., Rahway, New Jersey, USA.
Matthew L RizkMerck & Co., Inc., Rahway, New Jersey, USA.
Wendy PainterRidgeback Biotherapeutics, Miami, Florida, USA.
Wayne HolmanRidgeback Biotherapeutics, Miami, Florida, USA.
Susanne SardellaSimulations Plus, Cognigen Corporation, Buffalo, New York, USA.
George PainterEmory University School of Medicine, Atlanta, Georgia, USA.
Julie A StoneMerck & Co., Inc., Rahway, New Jersey, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molnupiravir, an orally administered drug for the treatment of mild-to-moderate COVID-19, is a prodrug of the ribonucleoside β-D-N4-hydroxycytidine (NHC). NHC incorporation in the SARS-CoV-2 RNA strand causes an accumulation of deleterious errors in the genome, resulting in reduced viral infectivity and replication. Exposure-response (E-R) analyses for viral RNA mutation rate and virologic outcomes were conducted using data from three phase 2/3 studies of molnupiravir (P006, MOVe-IN, and MOVe-OUT). Three dose levels (200, 400, and 800 mg every 12 hours [Q12H]) and placebo were evaluated. E-R datasets were generated for SARS-CoV-2 RNA mutation and longitudinal SARS-CoV-2 RNA viral load. E-R models were defined for RNA mutation rate and viral load change from baseline at days 5 and 10. The models supported plasma NHC AUC

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentCytidineHydroxylaminesSARS-CoV-2AdultBiomarkersCOVID-19Dose-Response Relationship, DrugFemaleHumansMaleMiddle AgedRNA, ViralTreatment OutcomeViral LoadAntiviral AgentsBiomarkersCytidineHydroxylaminesmolnupiravirRNA, Viralexposure‐responselow‐frequency nucleotide substitutionsNHCpharmacokinetics‐pharmacodynamicsSARS‐CoV‐2viral loadvirologic outcomesβ‐D‐N4‐hydroxycytidine

Identifiers

PMID40138219
PMCPMC11939005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.